Decibel Therapeutics Company
Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technology and our expertise in inner ear biology. We are leveraging our platform to advance our pipeline of preclinical gene therapy programs that are designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders.
Headquarters:
Cambridge, Massachusetts, United States
Number Of Exists:
51-100
Total Funding:
189.2M
Founded Date:
2015
Employee Number:
51-100
Last Funding Type:
Series D
Investor Type:
IPO
Investors Number:
16
Last Funding Date:
2020
Technology:
Other
Funding Status:
IPO
Estimated Revenue:
$10M to $50M
Industry:
Biotechnology, Gene therapy, Medical Device, Therapeutics